Published Date: 26 Apr 2023
In general, muscle function gets better during adolescence and gets worse as we get older. One such type of muscle deterioration that is primarily brought on by aging naturally is sarcopenia. Asians have lower rates of.
Read Full NewsWomen living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according to a multiyear analysis involving more ...
In a study of more than 100,000 screening mammograms, researchers demonstrated the potential of an AI tool to help identify women at higher risk of developing interval breast cancer, which is breast cancer that is diagnosed ...
Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates (ADCs). These treatments pair an antibody that targets ...
1.
Hybrid imaging test combines antibody and radioisotope for early lung cancer detection
2.
Kate Middleton Announces Major Cancer Update
3.
Legal, Recreational Marijuana Linked to Higher CUD Prevalence.
4.
The top three drugs for multiple myeloma treatment upfront are four.
5.
The most precise research tools for the deadliest blood cancer have been developed.
1.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
2.
Exploring Innovative Solutions for Infantile Hemangioma Treatment
3.
Understanding Lymphedema: Symptoms, Causes, and Treatment
4.
Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer
5.
Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
4.
Efficient Management of First line ALK-rearranged NSCLC - Part V
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation